ADHD Clinical Trial - A Double-Blind Comparison of Concerta & Placebo in

Status Completed

Clinical Trial Summary

This is a double-blind, placebo-controlled study using daily doses of up to 1.3 mg/kg/day of Concerta in the treatment of adults with the DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD) (childhood onset). We hypothesize ADHD symptomatology in adults with DSM-IV ADHD will be responsive to Concerta treatment and Concerta-associated response of ADHD symptomatology in adults will be sustained over time.

Clinical Trial Description

Concerta was specially developed to replace three-times-a-day IR methylphenidate, making it an ideal option for patients with ADHD. Moreover, the once-a-day administration of Concerta secures a steady delivery of methylphenidate across the day, minimizing the well-known risks of peaks and valleys of IR methylphenidate, which could offer an added advantage to the pharmacokinetic advantage of once-a-day administration. Despite these putative advantages, whether this new delivery system will lead to the same results as those documented with immediate-response methylphenidate in the treatments of adults with ADHD requires empirical corroboration. To this end we are conducting a randomized controlled clinical trial to evaluate the short- and medium-term safety and efficacy of Concerta in the treatment of adults with ADHD with and without co-morbid psychiatric disorders. We also wish to examine the role of genetics in predicting ADHD treatment response to Concerta. There is growing literature that supports the role of genetic factors in treatment response in youth with ADHD, and we seek to further explore this relationship in adults.

The proposed study includes the use of a 34-week design to document the response rate, assessment of the impact of Concerta on functional capacities (quality of life, psychosocial function) and cognition, and careful assessment of safety and tolerability. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

ADHD
Attention Deficit Disorder with Hyperactivity

Clinical Trial Details

NCT number	NCT00181571
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Completed
Phase	Phase 4
Start date	June 2003
Completion date	August 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03148782` - Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase	N/A
Recruiting	`NCT06038942` - Formal Versus Informal Mindfulness Among University Students With Self-reported ADHD, Nonsuicidal Self-injury, or Stress	N/A
Not yet recruiting	`NCT06456372` - Digital Health Intervention for Children With ADHD	N/A
Completed	`NCT05518435` - Managing Young People With ADHD in Primary Care Study
Active, not recruiting	`NCT04978792` - Does Cultivating Self-compassion Improve Resilience to Criticism and Improve Mental Health in Adults With ADHD?	N/A
Completed	`NCT03216512` - Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD	N/A
Completed	`NCT02900144` - Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)	N/A
Not yet recruiting	`NCT02906501` - Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral Disturbances	N/A
Completed	`NCT02829528` - Little Flower Yoga for Kids: Evaluation of a Yoga and Mindfulness Program for Children With Increased Levels of Emotion Dysregulation and Inattention	N/A
Completed	`NCT02562469` - ACTIVATE: A Computerized Training Program for Children With ADHD	N/A
Terminated	`NCT02271880` - Improving Medication Adherence in ADHD Adolescents	N/A
Recruiting	`NCT02255565` - Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study	Phase 4
Completed	`NCT02463396` - Mindfulness Training in Adults With ADHD	N/A
Terminated	`NCT01733680` - Amiloride Hydrochloride as an Effective Treatment for ADHD	Early Phase 1
Completed	`NCT01673594` - Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist	Phase 4
Completed	`NCT02300597` - Internet-based Support for Young People With ADHD and Autism - a Controlled Study	N/A
Active, not recruiting	`NCT01137318` - Combined Cognitive Remediation and Behavioral Intervention for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)	Phase 2
Completed	`NCT01404273` - Functional MRI of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder	N/A
Completed	`NCT00586157` - Study of Medication Patch to Treat Children Ages 6-12 With ADHD	Phase 4
Completed	`NCT00573859` - The Reinforcing Mechanisms of Smoking in Adult ADHD	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms